| Literature DB >> 31410244 |
Kuniyasu Ikeoka1, Nagahiro Nishikawa1, Masayuki Sakakibara1, Keisuke Kawamoto2, Shiro Hoshida3.
Abstract
A 46-year-old man presented with advanced and complete atrioventricular block. He was diagnosed with human leukocyte antigen-B27-positive ankylosing spondylitis (AS) and treated with nonsteroidal anti-inflammatory drugs for AS. The severe atrioventricular block spontaneously improved and resolved after 3 months of therapy. Sequential cardiac magnetic resonance imaging demonstrated transient myocardial high-intensity signals in the basal septum close to the membranous portion of the septum. A pacemaker was not needed because of the reversible atrioventricular block.Entities:
Keywords: HLA‐B27; ankylosing spondylitis; atrioventricular block; cardiac magnetic resonance
Year: 2019 PMID: 31410244 PMCID: PMC6686291 DOI: 10.1002/joa3.12218
Source DB: PubMed Journal: J Arrhythm ISSN: 1880-4276
Figure 1Electrocardiography showing advanced and complete atrioventricular block on the day of admission (A). The atrioventricular block spontaneously improved to a Mobitz Ⅱ second‐degree atrioventricular block next day (B) and to a first‐degree atrioventricular block 2 wk after initiating celecoxib therapy (C). After 3 mo, the PR interval returned to normal limits (D). The recurrence of prolonged PR interval was observed 6 mo later with the upregulated inflammatory markers (E). The paper speed of the electrocardiogram was 12.5 mm/s only in Figure 1A. The paper speed of other figures (B‐E) was usual (25 mm/s)
Figure 2The patient was examined in the active phase by cardiac magnetic resonance imaging when he presented with the Mobitz II second‐degree atrioventricular block. Fat‐suppressed T2‐weighted magnetic resonance imaging showed high‐intensity signals in the basal septal myocardium close to the membranous septum (white arrow) (A). Late gadolinium enhancement indicated high‐intensity signals in the same area. (white arrowhead) (B). The high‐intensity signals disappeared in the fat‐suppressed T2‐weighted (C) and late gadolinium enhancement imaging (D) at 5 mo after initiating therapy